Δευτέρα 10 Δεκεμβρίου 2018

No Survival Benefit Found With Durvalumab in Head and Neck Cancer - Targeted Oncology

Bohen.jpg

No Survival Benefit Found With Durvalumab in Head and Neck Cancer  Targeted Oncology

AstraZeneca has reported that the phase III EAGLE trial has missed its primary endpoint, as patients with recurrent or metastatic head and neck squamous cell ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EayQCm

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.